Prosensa Finds Path Forward For Drisapersen In DMD Drug Revival
This article was originally published in Pharmaceutical Approvals Monthly
The Dutch company received positive news for its development programs in the U.S., an encouraging sign for a disease space that has been flailing in recent months due to unclear clinical endpoints.
You may also be interested in...
The New Jersey-based biotech has not lost its optimism after a setback in Europe for its lead product and is showing growth in other areas.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.